CoChat

Dormant Cancer Cells Contribute to Residual Disease in a Model of Reversible Pancreatic Cancer

Open access
Lin, Wan-chi, Rajbhandari, Nirakar, Liu, Chengbao, Sakamoto, Kazuhito, Zhang, Qian, Triplett, Aleata A., Batra, Surinder K., Opavsky, Rene, Felsher, Dean W., DiMaio, Dominick J., Hollingsworth, Michael A., Morris, John P., Hebrok, Matthias, Witkiewicz, Agnieszka K., Brody, Jonathan R., Rui, Hallgeir, Wagner, Kay-Uwe · 2013 · Cancer Research
Cited by 81

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

The initiation and progression of pancreatic ductal adenocarcinoma (PDAC) is governed by a series of genetic and epigenetic changes, but it is still unknown whether these alterations are required for the maintenance of primary and metastatic PDAC. We show here that the c-Myc oncogene is upregulated throughout the entire process of neoplastic progression in human PDAC and in genetically engineered mice that express mutant Kras. To experimentally address whether c-Myc is essential for the growth and survival of cancer cells, we developed a novel mouse model that allows a temporally and spatially controlled expression of this oncogene in pancreatic progenitors and derived lineages of the exocrine pancreas. Unlike previous reports, upregulation of c-Myc was sufficient to induce the formation of adenocarcinomas after a short latency without additional genetic manipulation of cell survival pathways. Deficiency in Cdkn2a increased the rate of metastasis but had no effect on tumor latency or c-Myc–mediated cancer maintenance. Despite a macroscopically complete regression of primary, metastatic, and transplantable tumors following the ablation of c-Myc, some cancer cells remained dormant. A significant number of these residual neoplastic cells expressed cancer stem cell markers, and re-expression of exogenous c-Myc in these cells led to rapid cancer recurrence. Collectively, the results of this study suggest that c-Myc plays a significant role in the progression and maintenance of PDAC, but besides targeting this oncogene or its downstream effectors, additional therapeutic strategies are necessary to eradicate residual cancer cells to prevent disease recurrence. Cancer Res; 73(6); 1821–30. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-12-2067

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 81

Metadata

Authors
Lin, W.-C., Rajbhandari, N., Liu, C., Sakamoto, K., Zhang, Q., Triplett, A. A., Batra, S. K., Opavsky, R., Felsher, D. W., DiMaio, D. J., Hollingsworth, M. A., Morris, J. P., Hebrok, M., Witkiewicz, A. K., Brody, J. R., Rui, H., & Wagner, K.-U.
Venue
Cancer Research
Published
2013-03-14
Volume
73
Issue
6
Pages
1821-1830
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2108002446
Cited by
81
References
9
FWCI
2.53
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dormant Cancer Cells Contribute to Residual Disease in a Model of Reversible Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-2067
The paper
Lin, W.-C., Rajbhandari, N., Liu, C., Sakamoto, K., Zhang, Q., Triplett, A. A., Batra, S. K., Opavsky, R., Felsher, D. W., DiMaio, D. J., Hollingsworth, M. A., Morris, J. P., Hebrok, M., Witkiewicz, A. K., Brody, J. R., Rui, H., & Wagner, K.-U. (2013). Dormant Cancer Cells Contribute to Residual Disease in a Model of Reversible Pancreatic Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-2067

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.